Lexicon Pharmaceuticals and Bristol-Myers Squibb, though both in pharma, are leagues apart in scale, profitability, and risk.

CAR-T pipeline advances, with blood cancers at the forefront of development, driving new treatment innovations.

Bristol-Myers Squibb finds itself in the billionaire investors’ bargain bin, but with some surprisingly luxe packaging. The ...